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Abstract
QUESTIONS UNDER STUDY: The use of placebo out-
side of randomised controlled trials raises ethical and legal
issues. So far, patients’ perspectives have been considered
only in quantitative studies. These studies did not distin-
guish between pure placebos (no pharmacological effect)
and impure placebos (pharmacological ingredient, but no
disease-specific effect). The aim of our study was to ex-
plore patients’ conceptualisation, experiences and attitudes
regarding the use of placebos in daily clinical practice.
METHODS: Qualitative study with a convenience sample
of 12 patients and semistructured interviews. The inter-
views were digitally recorded; full transcripts were ob-
tained. The information was analysed in accordance with
the qualitative content analysis method.
RESULTS: The definition of placebo given by the par-
ticipants mostly matched the common understanding of
a pure placebo. Most participants supposed that placebos
were mainly effective in diseases in which psychological
influences play an important role. Furthermore, most par-
ticipants believed that placebos themselves mainly worked
via psychological effects. The acceptance of a hypothetical
earlier use of a placebo depended on the success of the ther-
apy.
CONCLUSION: Patients were not aware of the differences
between pure and impure placebos. Even regarding pure
placebos, patients were more open than many physicians
would expect. Trust between the patient and the general
practitioner is an important element of the acceptance of
a placebo. Appropriate communication could further in-
crease the acceptance. Further research is needed to adapt
the information given to the patient about possible placebo
therapy.
Key words: placebo; general practitioners; patients’
perspective; qualitative study
Introduction
In randomised pharmaceutical clinical trials, the use of
placebos is quite common. However, placebos are occa-
sionally also used in daily practice, in a hospital environ-
ment as well as in an outpatient setting [1–5]. Meissner et
al., for example, showed that 45% of German general prac-
titioners (GPs) used a pure placebo (no pharmacological
active substance) [6, 7] at least once a year (median use 5
times/year) and a much higher rate was revealed for impure
placebos (pharmacological ingredients but no disease-spe-
cific effect), with a median use of 20 times per year [2].
Different aspects of placebo use have been addressed in
several studies in the context of randomised controlled tri-
als (RCTs) [8–13]. Recent studies have also focused on the
use of placebos outside RCTs, mainly assessing quantitat-
ive aspects [1–3] or discussing the legal and ethical contro-
versy about the use of a placebo [14–18]. In these studies
mainly the perspectives of health professionals, research-
ers or ethicists have been assessed [4, 5, 14, 16, 19]. Most
physicians agreed that placebos played an important role
in daily practice, for example, to calm the patient or as a
supplemental therapy [4]. But their use was associated with
ethical and legal uncertainties, especially regarding decep-
tion and lack of informed consent.
Interestingly, only a few studies have addressed the pa-
tient’s perspective [15, 20–25]: three studies were qual-
itative studies on the perception and conceptualisation of
placebos in RCTs [23–25] and all the other studies were
based on cross-sectional questionnaires. Lynöe [15] et al.
provided patients with a case vignette of a patient expecting
penicillin and a physician who did not see any medical
reason for it. In this situation, a majority of patients would
accept the physician using a placebo. A Swiss study [21]
showed that patients were open to placebos, but wanted to
be well informed. A study in New Zealand [20] found that
patients were amenable to the use of placebos, but also re-
vealed a lack of knowledge about the placebo effect and
that many patients believe that the placebo effect depends
on personality traits.
The aim of our study was to explore patients’ conceptu-
alisation, experiences and attitudes regarding the use of
placebos in daily practice. Furthermore, we were partic-
ularly interested in the conditions under which patients
would accept the use of a placebo in daily practice. In our
study we used the term placebo for both pure and impure
placebos.
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Methods
The Research Ethics Committee of the Canton of Zurich,
Switzerland, approved the study (KEK-StV-Nr 69/09). All
information was treated confidentially. Informed consent
was given verbally (and audiotaped) after participants were
informed about the study aim and study protocol. The Eth-
ics Committee did not oppose this procedure to obtain in-
formed consent.
Sampling
We used the consolidated criteria for reporting qualitative
research (COREQ) to organise and report our results [26].
For the recruitment of our study participants, we asked
the GPs participating in our earlier study [27] to pin up
an information sheet in their general practice. All patients
over 18 were eligible and prior experience with placebos or
knowledge about placebos was not mandatory. In accord-
ance with our first study, we chose a convenience sample
of 12 participants. Interested patients were included in the
study consecutively; the study’s purpose and design were
explained before the participants gave their consent for
participation. The participants were specifically asked not
to inform themselves about placebos before the interview,
since we were interested in their individual, unprejudiced
opinions about placebo. No interested participants had to
be excluded.
Interviews
On the basis of our literature search (databases: Medline®,
Embase®; search terms, or MeSH/Emtree terms where
available: “placebo”, “concept/conceptualisation”, “eth-
ics”, “general practitioners”, “qualitative study”, “pa-
tients”, “expectations”), we developed a semistructured in-
terview guide with 14 open-ended questions. A preliminary
interview guide was pilot-tested with two patients to ensure
that the questions were clear and comprehensible. The in-
terviews were conducted between April and June 2009 at
the participants’ workplace or home by one author (HT);
in all interviews no additional person was present. Digital
records were obtained and field notes were taken during
the interviews. During the interview it was confirmed –
with further explanations where necessary – that the parti-
cipants understood the questions correctly. The duration of
the interviews was between 20 and 35 minutes (mean 26.5
minutes, median 25.2 minutes).
Questions
The participants were asked about their definition of a
placebo, their attitudes towards placebo therapies (asso-
ciations, moral dilemma with deception, conditions for
placebo use) and experiences with a placebo therapy. Fur-
thermore, two short case descriptions were orally presen-
ted:
First case
“Assume that you are suffering from a fatal condition
where no specific therapy exists. Should your physician
prescribe medication anyway, even though its effect is dis-
putable?”
Second case
“Imagine you find out that your physician has treated you
with a placebo. Your physician was fully aware of the
chosen therapeutic option, but did not clearly communicate
his decision. What is your reaction and how do you feel
about this physician?”
“Would you react differently if the chosen treatment had
worked?”
Analysis
The interviews were transcribed literally (by HT) and sub-
sequently analysed in accordance with to the qualitative
content analysis method [28]. Qualitative content analysis
is a method with categories as the main instrument; the
method allows both deductive and inductive category
building. In a first step, categories can be built deductively
in accordance with a theoretical framework; further cat-
egories can also be built during analysis where needed,
allowing an inductive approach. We established an initial
coding system in accordance with the themes in our inter-
view guide, including headings and subheadings which we
composed before analysis. During the coding process with
Atlas.ti-software (version 5.0, Scientific Software Devel-
opment, 2004) the categories were slightly modified and
supplemented. The final coding system is listed in table 1.
First, the coding process was undertaken independently by
three authors (HT, CH, RF). HT is male, CH and RF are
female; HT and RF were senior medical students, CH is
a sociologist (PhD) and post-doctoral researcher. RT is a
male clinician (GP) and postdoctoral researcher, NB is a fe-
male physician and postdoctoral researcher. In the case of a
disagreement with the coding system, the three coders dis-
cussed the disagreement and consulted a fourth researcher
(RT) where necessary. After the coding process, a synthesis
of the findings was compiled, with discussion of the results
with a fourth and fifth researcher (RT, NB).
Results
Participants
After giving informed consent, 12 patients were included
in our study, of whom 5 were female and 7 were male. The
average age was 64 years (range 38‒76 years); the general
practices that recruited patients were in Zurich, so all par-
ticipants lived in the Canton Zurich. Six out of 12 were
feeling healthy at the time the interview was conducted.
Details about the participants are shown in table 2. The res-
ults are presented in accordance with the hierarchical final
version of our categorising system. The numbers of parti-
cipants giving a certain statement are mentioned in order to
quantify and weigh different statements.
Definition and association of placebo
All participants defined placebo quite similarly, as a sub-
stance without any pharmacological active ingredientI,
which fits the definition of a pure placebo. We asked the
participants what they associated with the term placebo.
Eight out of 12 (66.7%) stated that the term was neutrally
associatedII; 3 (25.0%) of the participants had a positive
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association, 1 participant (8.3%) stated a negative associ-
ation.
I“… a placebo is a drug without any pharmacological
substance in it, but it helps the patient who believes in
it.” (P7, m, 76y.)
II“Placebo sounds neutral to me, since it has either no
or a positive effect…” (P8, m, 66y)
Conceptualisation of placebo
All participants believed that placebos were effective in
that they could ameliorate symptomsIII. Nine out of the
12 participants (75.0%) stated a belief in an association
between body and mind; some related their own exper-
iences with examples of the perception of side effects
(“nocebo”) rather than of the experience of a placeboIV.
III“Body and mind are a unit. If the mind believes in
something it may have positive or negative effects on the
body.” (P5, m, 67y)
IV“… from my own experience I think a placebo can
have the same effect as a real drug. I know that… be-
cause when I read the side effects in the prescribing in-
formation, I will have those symptoms.” (P1, f, 75y)
Placebo effect depending on patient or disease
characteristics
We asked the participants whether they believed the
placebo effect was related to certain patient or disease char-
acteristics.
Patient characteristics
Ten of the 12 participants (83.3%) believed that a placebo
effect depended on specific patient characteristics; 2
(16.7%) were not completely sure. Three (25.0%) believed
that children were more susceptible to a placebo effect
than adults; 3 out of the 12 participants (25.0%) stated
that the placebo effect might be higher in psychiatric pa-
tients, in patients who were psychologically vulnerableV,
or in less intelligent patients. Two participants (16.7%) be-
lieved that patients expecting drug therapy when consulting
a GP might be more susceptible to placebo.VI
Disease characteristics
Ten participants (83.3%) believed that diseases in which
psychological factors play an important role were more
prone to a placebo effect than, for example, diseases that
were clearly somatic, such as cancer or a bone fracture. The
participants often used terms such as “light disease” and
“heavy disease” without a clear indication of how they pre-
cisely differentiated the two groupsVII, VIII.
V“I think a person who is psychologically vulnerable is
more likely to react to a placebo.” (P9, m, 68y)
VI“(…) probably in patients who are expecting a drug
therapy from the physician.” (P12, f, 65y)
VII“If I am severely ill, for example, if I break my arm,
I’d expect that a placebo won’t heal the fracture. So in
real diseases there will probably be no influence, except
when the disease has a psychological aetiology.” (P11,
m, 66y)
VIII“I would expect that a placebo can help in diseases
which are not severe and where a spontaneous cure
could be expected.” (P12, f, 65y)
Use and acceptance of placebos
A question in the interview guide addressed participants’
earlier experiences with placebo treatments. To avoid con-
fusion, we supplied the following definition of a placebo
Table 1: Categorisation system in the content analysis.
A Conceptualisation of placebo
A1 Definition of placebo
A2 Association – how do the participants associate the term “placebo” (positive/neutral/negative)?
A3 Reaction to placebo depending on patient characteristics
A4 Reaction to placebo depending on disease characteristics
B Use and acceptance of placebo
B1 Participants experiences with placebo (pure, impure)
B2 Placebo acceptance
B3 Moral dilemma – deception vs informed consent
B4 Diction – how should a general practitioner communicate placebo therapy to his patients?
B5 Placebo therapy in the case of no therapeutic options
B6 Reaction to a former placebo therapy
Table 2: Characteristics of participating patients.
Sex Age Education and profession State of health
1 F 75 Professional school, retired Cardiovascular disease
2 M 74 University, retired prosecutor Healthy
3 F 42 Higher vocational diploma, merchant Pulmonary disorder
4 M 66 University, teacher Healthy
5 M 67 University, businessman Urological disease
6 F 38 Higher vocational diploma, businesswoman Healthy
7 M 76 Professional school, retired, travel agent Healthy
8 M 66 University, business consultant Healthy
9 M 68 University, retired, former businessman Ophthalmological disease
10 F 67 Professional school, retired, former secretary Healthy
11 M 66 Higher vocational diploma, retired, businessman Healthy
12 F 65 Professional school, businesswoman Rheumatic disease
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before further questions were asked. We used our own
definition, which was based on discussions in the literature,
mainly on two papers [7, 29]:
“A placebo is a pill or procedure that does not influence
the health impairment directly, but indirectly, for ex-
ample through psychosocial mechanisms effecting im-
provement.”
Six participants (50.0%) stated that they had experiences
with a placebo (vitamin C was given as example when the
question was not clear enough), such as consumption of
vitamin C during influenza seasonIX. Four of these 6 parti-
cipants reported positive experiences whereas the two oth-
ers were unsure about the effect. Four of the 12 participants
(33.3%) mentioned positive experiences with homoeopath-
ic or phytotherapeutic agents. Seven of the 12 participants
(58.3%) stated that the placebo effect was probably part of
the effect of homoeopathic agents, and all 4 participants
with experiences of phytotherapy believed in a true biolo-
gical effectX.
IX“My wife and I, we occasionally consume vitamin
C, especially during the winter season; I thought to
strengthen my resistance against viral infections with it.
But I’m not so sure whether it works, since I’ve never
observed it carefully enough” (P9, m, 68y)
X“I tried Echinacea once; I guess it has an effect, but
just a little one. I don’t know whether this is a placebo.”
(P3, f, 42y)
Conditions for the use of placebo and the moral
dilemma
The participants were asked under what conditions they
would accept placebo therapy. Two of the 12 participants
(16.7%) would not accept placebo therapy at all, mostly
because they felt they were not being taken seriously if
a placebo treatment was prescribed for their symptomsXI.
The remaining 10 participants (83.3%) would accept
placebo therapy if the physician-patient relationship was
solid and trustfulXII, XIII. Concerning deception, there were
various attitudes: 7 out of the 10 wanted deception, since
they were afraid that they would miss the effect if they
knew that a placebo and not a pharmacologically active
substance was given to themXIV, XV.
We asked the participants for their opinion about the moral
dilemma of giving a patient a placebo and concealing its
true identity. Furthermore, we asked what information
should be given if a placebo treatment were to be pre-
scribed. The two participants not accepting the placebo
therapy insisted on full information and did not accept any
deceptionXVI. Ten of the 12 participants (83.3%) were very
ambivalent, particularly between their rights and will to
get all information about current therapies and their fear of
losing the effect if the placebo were given without decep-
tionXVII, XVIII. Most participants stated they preferred gen-
eral information, such as “this therapy has helped others in
the past”.
XI“In this case I would actually think he is fooling me!”
(P8, m, 66y)
XII“…[the acceptance of placebo therapy] depends on
whether or not I trust my GP. If I were to go to an un-
known physician for the first time and receive a placebo,
I would be irritated by that.” (P10, f, 67y)
XIII“My acceptance [of placebo therapy] depends on the
trust I have in my GP. If I imagine my current GP I don’t
think I have any problem at all with getting a placebo
therapy.” (P8, m, 66y)
XIV“I can imagine getting a placebo, but in that case the
GP should deceive me.” (P5, m, 67y)
XV“If I don’t know that it is simply sugar and I believe in
the drug and my GP is telling me to take it, then I will
take it. I’ll take everything that my physician tells me to
take.” (P7, m, 76y)
XVI“I want to know everything, exact details and why he
thinks this therapy would be helpful…” (P2, m, 74y)
XVII“I would not expect an open-label administration of
placebo, since it would not work anymore in that case.”
(P6, f, 38y)
XVIII“I am not so sure, I am afraid if I get too much in-
formation the therapy won’t work; if I get too little in-
formation I would probably feel misled.” (P3, f, 42y)
Case presentations
In the first case, 2 out of the 12 participants (16.7%) did
not approve of the prescription of a placebo under any
circumstancesXIX. The remaining 10 participants (83.3%)
would approve the use of a placebo, depending on different
factors. Some of them would try a placebo therapy in the
case of a “light” disease, defining this as a disease that most
likely would disappear independently of a therapy. But
most of the participants would rather consider a placebo
treatment in the case of a hopeless situationXX, XXI.
XIX “No, I do not accept that… if my physician does pre-
scribe a medication, I want one with a specific effect.”
(P1, f, 75y)
XX“The acceptance of the therapy depends on the sever-
ity of the disease. I mean if I am seriously ill and I
don’t see any chances for myself, I would be ready to try
everything possible.” (P10, f, 67y)
XXI“For me it is crucial whether the disease is severe or
not, it particularly depends on the fact of whether the
disease will get worse by waiting or not.” (P5, m, 67y)
In the second case, 7 of the 12 participants (58.3%) would
have accepted their physician’s decision, independently of
the result. Two of the participants (16.7%) would not ac-
cept this from their physician and would immediately
choose a different physician. The remaining 3 participants
(25.0%) would have different acceptance depending on the
result of the therapy, but trust in the physician would have
been distorted. Sometimes even self-confidence seemed to
be distortedXXII.
XXII“If it really would have worked… well… then I actu-
ally have to ask myself: what kind of an idiot I am to be
deceived by a placebo?” (P2, m, 74y)
Discussion
For the first time, the conceptualisation and attitudes of pa-
tients regarding placebo therapy in daily practice, outside
of medical research, has been assessed with a qualitative
approach. Interestingly, within a solid and trustful patient-
physician relationship the majority of participants would
accept a placebo therapy.
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Definition and concept of a placebo
The definitions given and the rather neutral or positive as-
sociations of the term placebo are consistent with an earli-
er Swiss study in 414 patients, in which similar definitions
were given and the term was mainly neutrally (63%) or
positively (23%) associated [21]. Furthermore, GPs in our
first qualitative study [27] and patients in this study seemed
to have similar definitions of placebo in mind, reflected in
similar wording to describe the term “placebo”. Different
associations of the term placebo were found in a French
study [22] where the majority assessed placebo as negative,
which could have been influenced by the different cultural
or language background.
All participants believed that symptoms could improve
with a placebo. Most participants stated that placebos were
mainly effective in diseases in which psychological influ-
ences played an important role. This might be explained by
an earlier statement in which most participants supposed
that placebos themselves mainly worked via psychological
effects. Some participants postulated a “placebo-personal-
ity”; the participants mainly expected psychologically vul-
nerable patients to be more prone to a placebo effect than
others. These findings are consistent with earlier studies
with patients [15, 20–25]. In a cross-sectional survey of
300 patients [22], 91% of the participants believed that
the placebo effect depended on the patient’s personality
and 83% stated that patients responding to a placebo were
psychologically vulnerable. The conceptualisation of the
disease played an important role in the acceptance of a
placebo. In a qualitative study, Bishop et al. [23] inter-
viewed participants in a trial addressing irritable bowel dis-
ease. The authors showed that a holistic approach to the ae-
tiology of the symptoms resulted in a higher acceptance of
(possible) placebo therapy.
Use and acceptance of a placebo therapy
Interestingly, even though most of the participants stated
that they believed that placebo therapy played a role
primarily in “light” diseases, most of the participants would
consider taking a placebo in the case of a severe disease if a
specific therapy was lacking. This finding reflects the fact
that people were maybe more likely to accept placebos in
situations in which no effective therapy could be offered.
Lacking therapeutic options as reason to use placebo as
well as, for example, homeopathic approaches is a well-
known phenomenon in medicine [30]. Kaptchuk et al.
showed that hope and expectations might be important
factors in the placebo concept as well [25]. Some ethicists
regarded the use of placebo in a clinical situation where
no specific treatment was available as ethically justifiable
[31].
Nevertheless, under certain circumstances there was ac-
ceptance of the use of placebo in daily practice; the trust
in a good physician-patient relationship played the most
important role in this acceptance. This has various implic-
ations. The participants expected their GP to know the
patient and to believe personally that the patient would be-
nefit from the treatment. Furthermore, the disease might
not be impaired by the placebo (or by omitting the non-
placebo therapy). The higher acceptance of a placebo with
a positive outcome than an adverse outcome might be ex-
plained by this fact. This has also been shown in an earlier
study where the acceptance of a placebo was higher in the
case of a beneficial outcome of the disease [32]. Fässler
et al. showed that patients’ acceptance of placebo use was
higher if the prescribing physician himself believed in pos-
sible treatment effects [21]. Linde et al. discussed – with
special regard to homeopathy – whether this could still be
regarded as a placebo therapy if the physician was con-
vinced of the treatment effect [33].
Communication in the case of placebo use
Only a minority (2/12, 16.7%) would not accept a placebo
at all. But even the patients that were open to placebo use
under certain circumstances would prefer an indirect ex-
planation (e.g. “this therapy has helped other patients in
the past”) to a direct notification that they would receive
a placebo. Unfortunately, we were not able to find factors
helping to distinguish the placebo-acceptors from the
placebo-deniers. Different attitudes towards involvement
in clinical decisions have been shown in hospital patients
as well as in patients of general practices [34, 35] and both
these studies recommended individual assessment of pa-
tient preferences.
Strengths and limitations
Because of the qualitative design, quantitative conclusions
cannot be drawn. Our group of 12 participants was very
small and had limited geographical and cultural variation.
There might be an additional selection bias due to the re-
cruitment process: firstly, more patients with higher confid-
ence in their GPs could be recruited to participate in our
study; secondly, the announcement of the study patients
could have selected patients who had some idea what a
placebo was. Also the patients might have had different
awareness of the various contexts where placebos are used
and this might have influenced their answers. Furthermore,
our study sample was well-educated, older than the general
population and from urban regions: this limits generalis-
ability of the study results. Future research is needed to
confirm our findings with a better demographic balance of
the study population. Nevertheless, in our study we found
some well-differentiated thoughts of patients about the use
of placebo. We reached a good saturation with the number
of interviews as the coding system was not further adapted
for the last four interviews and in the last two interviews all
statements (e.g. definition of placebo) were similar to earli-
er interviews.
Conclusion
Patients were not aware of the differences between pure
and impure placebos, but even regarding pure placebos, pa-
tients were more open than many physicians would expect.
Trust between the patient and the GP is an important ele-
ment for the acceptance of placebo therapy. Appropriate
communication could further increase acceptance. Further
research is needed to adapt the information given to the pa-
tient about possible placebo therapy.
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